Caribou Biosciences Azioni (NASDAQ: CRBU)

Ultime notizie per Caribou Biosciences (NASDAQ:CRBU) Azioni

Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Caribou Biosciences Inc

News

Guidance

NeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly sales of $805.86 million which missed the analyst consensus estimate of $809.30 million by 0.43 percent. This is a 0.23 percent increase over sales of $804.03 million the same period last year.

Earnings

Earnings Misses

AHCO

AdaptHealth Q3 Sales $805.86M Miss $809.30M Estimate

Biotech

Health Care

General

TRDA

Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_05112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
EURUSD remains poised around 1.0878 as markets brace for the outcome of the highly anticipated US presidential election. With the world watching, the direction of the major currency pair will hinge significantly on the election results, where a victory for Donald Trump is likely to bolster the USD, potentially leading to a notable increase. Conversely, a win for Kamala Harris could see the USD decline by an average of 1-2%.
The impending volatility is not solely due to the election but amplified by the upcoming Federal Reserve meeting scheduled for Wednesday. The Fed is anticipated to cut interest rates slightly by 25 basis points. Market participants are keenly awaiting any forward guidance from the Fed, particularly with expectations leaning towards another rate reduction in December.
While significant economic data releases are also expected, these pivotal events may overshadow their impact.
<h3>Technical Analysis Of EUR/USD</h3>
<a href="https://www.benzinga.com/files/u117641/eurusdh4_71.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh4_71.png" style="height:280px; width:624px" /></a>
The EURUSD market has completed a growth structure reaching 1.0913, considered part of a third growth wave targeting 1.0950. After this target is achieved, a retraction to 1.0860 is anticipated, potentially forming a broad consolidation range around this level. Technical indicators, such as the MACD, suggest an upward trajectory, reinforcing the possibility of reaching 1.0960 before a corrective pullback to 1.0860.
<a href="https://www.benzinga.com/files/u117641/eurusdh1_72.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh1_72.png" style="height:280px; width:624px" /></a>
Support at 1.0872 has spurred the development of a growth impulse towards 1.0900, which is expected to be tested soon. Breaching this level could extend the growth wave towards 1.0950. The Stochastic oscillator supports this short-term forecast, indicating upward momentum with its signal line targeting the upper echelons around 80.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Technicals

Forex

Markets

Trading Ideas

EUR/USD Stabilises As US Presidential Election Unfolds

Leerink Partners analyst Mani Foroohar initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $17.

Price Target

Initiation

Analyst Ratings

CAMP

Leerink Partners Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $17

NURO

NeuroMetrix Reports Q3 2024 Sales Of $0.6M Vs. $1.2M YoY, With EPS Loss Of $(0.75) Compared To ($1.66) YoY

As of month-end, the Company operated approximately 185,000 bitcoin miners in data centers for both self-mining and hosting, representing a total energized hash rate of 21.8 EH/s. &nbsp;

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Says It Earned 369 Bitcoin In October From Its Owned Fleet Of Miners Vs. 345 In September

Select October 2024 Highlights
<ul>
<li>Record total average daily volume ("ADV") of $46.2 billion increased 40% compared to the prior year, and increased 2% compared to September 2024. These strong results were driven by total credit ADV of $15.0 billion, representing an increase of 19% compared to the prior year, and a decrease of 9% compared to September 2024. Record total rates ADV of $31.2 billion, which increased 54% compared to the prior year, and increased 9% compared to September 2024 levels, also contributed to the strong performance in October 2024.</li>
<li>Record total trading volume of $1.0 trillion on the platform increased 47% compared to the prior year, and increased 12% compared to September 2024.</li>
</ul>

MKTX

MarketAxess Announced Trading Volume For October 2024 With Total Average Daily Volume Of $46.2B, Up 40% YoY And +2% Compared To September 2024

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. The company reported quarterly sales of $167.824 million which beat the analyst consensus estimate of $167.010 million by 0.49 percent. This is a 10.44 percent increase over sales of $151.954 million the same period last year.

Earnings Beats

NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate

Leerink Partners analyst Christopher Liu downgrades IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowers the price target from $41 to $27.

Downgrades

IDYA

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27

Pseudonymous crypto analysts DonAlt and CryptoCred explored Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price trends and the impact of <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re">Tuesday&#8217;s presidential election</a>.
Bitcoin's Expected Trajectory
In the latest &#8216;Technical Roundup&#8217; <a href="https://www.youtube.com/watch?v=IhonU0vEFQE&amp;pp=ygURdGVjaG5pY2FsIHJvdW5kdXA%3D">episode</a>, DonAlt noted Bitcoin's recent surge to close to its all-time high before retreating below $70,000, calling the monthly close "catastrophic" after a key resistance retest.
He projected $49,000 as the first support level in the short term, with more robust support near $35,000 on a monthly timeframe, and in an extreme scenario, a possible drop to $16,000.
DonAlt attributes recent sluggish crypto market activity to positioning ahead of a potential Trump victory. He <a href="https://x.com/CryptoDonAlt/status/1853452002983813251">cautioned</a> on X that a Trump win might bring only modest short-term upside for Bitcoin, while a loss could trigger a sell-off, with a Harris win potentially causing an even steeper decline. Emphasizing flexibility, DonAlt highlighted the need for strategic preparation as election results unfold.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a>
Ethereum's Play
DonAlt also commented on Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance relative to Bitcoin, stressing the dependency of ETH/BTC strength on Bitcoin's movement. He shared his open position in a SOL/BTC trade.
Given the election uncertainty, DonAlt concluded, "I'm not going to trade in the next weeks, maybe months," stressing the importance of caution in the current environment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41709166/bitcoin-to-hit-100-000-by-january-2025-could-black-hole-effect-push-the-largest-crypto-to-">Bitcoin To Hit $100,000 By January 2025? Could &#8216;Black Hole Effect&#8217; Push The Largest Crypto To Never-Before-Seen Levels</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Veteran Traders Share 'Presidential Election Crypto Trading Roadmap,' Predict Heavy Volatility

<a href="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona" title="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona">https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona</a>

AMZN

Amazon Says Customers In West Valley Phoenix Metro Area Now Receiving Prime Air Drone Deliveries

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) reported quarterly earnings of $0.08 per share. This is unchanged from the same period last year. The company reported $1.02 billion in sales this quarter. This is a 12.64 percent increase over sales of $909.09 million the same period last year.

CLPBY

Coloplast Q4 EPS $0.08, Same YoY, Sales $1.02B Up From $909.09M YoY

RNAZ

Transcode Therapeutics Has Received Notice From The Nasdaq Stock Market To Grant Transcode's Request To Continue Its Listing On The Nasdaq Stock Market Subject To Certain Conditions To Regain Compliance

The Company anticipates releasing its financial results for the six months ended June 30, 2024, by the end of November.
 &nbsp;

HUBC

HUB Security Says Making Progress On All Fronts, With Steady Advancement In Existing Contracts; Aims To Strategically Position Itself For Significant Penetration Into US Market In Q1 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financials sector.
<h3 class="wp-block-heading">Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>)</h3>
<ul>
<li>Dividend Yield: 5.47%</li>
<li>Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $28 to $29 on Oct. 10. This analyst has an accuracy rate of 75%.</li>
<li>Barclays analyst Alex Scott maintained an Equal-Weight rating and raised the price target from $35 to $36 on Oct. 8. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Oct. 31, Lincoln National posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest LNC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png" alt="" class="wp-image-629784" style="width:694px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-768x704.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Heritage Commerce Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>)</h3>
<ul>
<li>Dividend Yield: 5.44%</li>
<li>Piper Sandler analyst Andrew Liesch maintained an Overweight rating and raised the price target from $10 to $12 on July 26. This analyst has an accuracy rate of 78%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay maintained an Outperform rating and increased the price target from $10.5 to $11.5 on July 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 24, Heritage Commerce posted in-line quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest HTBK news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png" alt="" class="wp-image-629786" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-768x715.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>Dividend Yield: 5.19%</li>
<li>Truist Securities analyst Brandon King maintained a Hold rating and raised the price target from $28 to $30 on Oct. 28. This analyst has an accuracy rate of 81%.</li>
<li>RBC Capital analyst Jon Arfstrom maintained a Sector Perform rating and increased the price target from $29 to $31 on Oct. 25. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Oct. 24, Columbia Banking System posted better-than-expected quarterly results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> trend in COLB stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png" alt="" class="wp-image-629787" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735699/archer-daniels-midland-yum-brands-and-3-stocks-to-watch-heading-into-tuesday">Archer-Daniels-Midland, Yum! Brands And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

Dividends

Pre-Market Outlook

COLB

HTBK

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 14.55 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $4.89 million which beat the analyst consensus estimate of $3.35 million by 46.09 percent. This is a 47.94 percent increase over sales of $3.31 million the same period last year.

STOK

Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $164 to $154.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $154

JP Morgan analyst Tessa Romero initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Overweight rating and announces Price Target of $38.

JP Morgan Initiates Coverage On Upstream Bio with Overweight Rating, Announces Price Target of $38

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company's shar...

Bank of America Securities Keeps Their Buy Rating on Caribou Biosciences (CRBU)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report) today and set a price target of $9.00....

Caribou Biosciences (CRBU) Receives a Buy from H.C. Wainwright

Caribou Biosciences (CRBU) has provided an update. Jason O'Byrne, CFO of Caribou Biosciences, is set to resign on September 27, 2024, to explore a ...

Caribou Biosciences Announces CFO Resignation and Succession Plan

Truist Financial analyst Jailendra Singh reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company's shares closed...

Truist Financial Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Warning: CRBU is at high risk of performing badly

ABUS

ALLO

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

Legal

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Management

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

Comments

Caribou Biosciences

Notizie

Ultime notizie per Caribou Biosciences (NASDAQ:CRBU) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO